1. Home
  2. UCL vs NSRX Comparison

UCL vs NSRX Comparison

Compare UCL & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo uCloudlink Group Inc.

UCL

uCloudlink Group Inc.

HOLD

Current Price

$1.45

Market Cap

52.8M

ML Signal

HOLD

NSRX

Nasus Pharma Ltd. Ordinary Shares

N/A

Current Price

$2.42

Market Cap

53.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UCL
NSRX
Founded
2014
2019
Country
Hong Kong
Israel
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.8M
53.5M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
UCL
NSRX
Price
$1.45
$2.42
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$19.67
AVG Volume (30 Days)
5.4K
161.7K
Earning Date
05-20-2026
03-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.22
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$1.98
52 Week High
$4.19
$9.99

Technical Indicators

Market Signals
Indicator
UCL
NSRX
Relative Strength Index (RSI) 43.59 34.25
Support Level $1.23 N/A
Resistance Level $1.67 $5.20
Average True Range (ATR) 0.09 0.31
MACD 0.00 0.02
Stochastic Oscillator 47.55 20.33

Price Performance

Historical Comparison
UCL
NSRX

About UCL uCloudlink Group Inc.

Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: